FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
Search
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Hypertension
Click here for more information on Hypertension
Tips to help you start your patient advocacy journey
Advocating for yourself as a patient can be daunting. Jeff Dunn, President of Union for International Cancer Control (UICC), shares some tips
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Winners of 2020 BVDzero Case Awards
Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Winners of BVDzero Scholarship Programme
Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
PRRS vaccine celebrates 25 years in Europe
Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
Vaccine prevent calf diarrhea
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
Vaccine bluetongue virus serotype 3 sheep cattle
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
New digital Tx collab with Click
New digital therapy collaboration with Click Tx
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.